ArticleMolecular therapy. Oncology2024

Discovery and preclinical development of a therapeutically active nanobody-based chimeric antigen receptor targeting human CD22.

Scott McComb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.